SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vaccinex-Privately held now-IMO looking to go public
VCNX 0.630-8.7%Oct 31 9:30 AM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: richardred who wrote (11)2/19/2021 12:40:53 PM
From: richardred  Read Replies (1) of 17
 
Vaccinex's stock soars toward record gain on record volume after deals with 'prominent' drug makers Published: Feb. 19, 2021 at 12:20 p.m. ET
By
Tomi Kilgore






Shares of Vaccinex Inc. VCNX, +113.59% soared toward a record rally on record volume Friday, after the biotechnology company announced the signing of multiple-project deals with two "prominent" pharmaceutical companies. The collaborations will focus on the use of Vaccinex's antibody discovery and novel viral display platform, ActivMAb, for antibody discovery. The names of the drug makers and the financial terms over the deals were not disclosed. The stock soared 119.9% in midday trading, making the stock the biggest gainer on major U.S. exchanges, even after paring an earlier gain of as much as 233.1%. Trading volume skyrocketed to 215.3 million shares, compared with the full-day average over the past 30 days of about 711,000 shares. Both the gain and the volume were the most for the stock since it went public in August 2018. It has now more than tripled (up 221.9%) over the past three months, while the iShares Nasdaq Biotechnology ETF IBB, +1.17% has rallied 21.5% and the S&P 500 SPX, -0.02% has gained 9.5%.

marketwatch.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext